Lundbeck is currently addressing requests specified in the letter, and is committed to making Carbella available in 2015, pending FDA approval. "We are working closely with the FDA
The company also announced Dropless media coverage from AAO meeting, where it introduced a new white paper, titled, "Making Dropless Cataract Surgery Possible". Imprimis currently provides two proprietary
After positive negotiations with major international affiliate marketers, Alternaturals is confident that the company will see significant growth in 2015 to warrant its own facility. As a result,
Approved in the EU in 2011, Esbriet is indicated for the treatment of adults with mild to moderate IPF. The CHMP recommendation includes data from the phase III
As previously announced, Islet Sciences and BHV have entered into a merger agreement that will combine the operations and development pipelines of the two companies. Upon closing of
Following a recent meeting with the U.S. Food and Drug Administration (FDA), Vaxart anticipates commencing human clinical trials in the first quarter of 2015. Start of Clinical Trials
The allowed claims cover inhibitors of PRMT5 and methods of cancer treatment with PRMT5 inhibitors. PRMT5 is implicated in several cancers, including blood cancers. Epizyme also announced the
Under the license agreement, Medivation will be responsible for all development, regulatory and commercialization activities for pidilizumab for all indications, including oncology. "Immuno-oncology is a significant area of
Certara will enhance its physiologically-based pharmacokinetic (PBPK) modeling and simulation platform to assess the bioequivalence of drugs absorbed through the skin, while also factoring in variability in specific
WCCT Global’s patient recruitment division "In-Site" is comprised of 12 key elements to ensure patient enrollment and retention. The rescue program that was effective as of October 1st
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.